Edition:
United States

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

1.99USD
13 Nov 2018
Change (% chg)

-- (--)
Prev Close
$1.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
32,099
52-wk High
$9.25
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Fibrocell Reports Third Quarter 2018 Financial Results
Tuesday, 13 Nov 2018 08:00am EST 

Nov 13 (Reuters) - Fibrocell Science Inc ::FIBROCELL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.FIBROCELL SCIENCE INC - BELIEVES CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q4 OF 2019.FIBROCELL SCIENCE - AS OF SEPT 30, HAD CASH AND CASH EQUIVALENTS OF ABOUT $16.1 MILLION AND WORKING CAPITAL OF ABOUT $14.6 MILLION.  Full Article

Fibrocell Receives Guidance From FDA On Phase 3 Clinical Trial Design For Fcx-007
Thursday, 25 Oct 2018 08:06am EDT 

Oct 25 (Reuters) - Fibrocell Science Inc ::FIBROCELL RECEIVES GUIDANCE FROM FDA ON PHASE 3 CLINICAL TRIAL DESIGN FOR FCX-007.FIBROCELL SCIENCE INC - COMPANY PLANS TO SUBMIT PHASE 3 PROTOCOL FOR FCX-007 TO FDA IN Q4 OF 2018 AND COMMENCE TRIAL IN FIRST HALF OF 2019.  Full Article

Fibrocell Announces FDA Fast Track Designation Of FCX-013
Wednesday, 5 Sep 2018 08:00am EDT 

Sept 5 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES FDA FAST TRACK DESIGNATION OF FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA.FIBROCELL SCIENCE - PLANS TO MANUFACTURE FCX-013 AT CGMP CELL MANUFACTURING FACILITY LOCATED IN EXTON, PENNSYLVANIA.  Full Article

Fibrocell Reports Cash And Cash Equivalents Of About $15.4 Million
Thursday, 9 Aug 2018 08:00am EDT 

Aug 9 (Reuters) - Fibrocell Science Inc ::FIBROCELL REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.FIBROCELL SCIENCE INC - BOARD IS CONDUCTING A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING STOCKHOLDER VALUE IN APRIL.FIBROCELL SCIENCE INC - BOARD HAS ESTABLISHED A SPECIAL COMMITTEE TO EXPLORE AND EVALUATE POTENTIAL STRATEGIC ALTERNATIVES.FIBROCELL SCIENCE INC - AS OF JUNE 30, CO HAD CASH AND CASH EQUIVALENTS OF ABOUT $15.4 MILLION.FIBROCELL SCIENCE INC - CURRENT CASH POSITION WILL BE ABLE TO FUND OPERATIONS INTO Q4 2019.  Full Article

Fibrocell Announces $6.0 Mln Registered Direct Offering Priced At-The-Market
Tuesday, 29 May 2018 09:20am EDT 

May 29 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES $6.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.FIBROCELL SCIENCE - ENTERED DEFINITIVE AGREEMENTS WITH INSTITUTIONAL INVESTORS FOR PURCHASE OF ABOUT 2 MILLION SHARES OF COMMON STOCK, AT $2.85/SHARE.FIBROCELL SCIENCE - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL AND PRE-CLINICAL DEVELOPMENT OF FCX-007 AND FCX-013.  Full Article

Fibrocell Announces One-For-Five Reverse Stock Split
Thursday, 24 May 2018 08:55am EDT 

May 24 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES ONE-FOR-FIVE REVERSE STOCK SPLIT.FIBROCELL SCIENCE - TO EFFECT 1-FOR-5 REVERSE STOCK SPLIT OF COMMON STOCK AT 5:00 PM ET TODAY.FIBROCELL SCIENCE - BEGINNING WITH OPENING OF TRADING ON MAY 25, COMMON STOCK WILL TRADE ON NASDAQ CAPITAL MARKET ON SPLIT-ADJUSTED BASIS.  Full Article

Fibrocell Reports Q1 Loss Per Share $0.11
Thursday, 10 May 2018 08:00am EDT 

May 10 (Reuters) - Fibrocell Science Inc ::FIBROCELL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 LOSS PER SHARE $0.11.  Full Article

Fibrocell Reports 2017 Financial Results And Recent Highlights
Monday, 19 Mar 2018 08:00am EDT 

March 19 (Reuters) - Fibrocell Science Inc ::FIBROCELL REPORTS 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.  Full Article

Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007
Tuesday, 30 Jan 2018 08:00am EST 

Jan 30 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB).FIBROCELL SCIENCE INC - FCX-007, CO'S GENE THERAPY CANDIDATE, IS BEING DEVELOPED IN COLLABORATION WITH INTREXON CORPORATION.  Full Article

Fibrocell Science Says Expects IND Filing Of FCX-013 In Q1 2018
Friday, 29 Dec 2017 08:56am EST 

Dec 29 (Reuters) - Fibrocell Science Inc ::FIBROCELL SCIENCE INC SAYS EXPECTS IND FILING OF FCX-013 IN Q1 2018 AND INITIATE SAFETY CLINICAL TRIAL IN 2018 - SEC FILING.  Full Article

BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

* FIBROCELL REPORTS ON INTERIM RESULTS AND PROGRESS OF PHASE 1/2 CLINICAL TRIAL OF FCX-007 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA